These findings suggest that FFA treatment in L02 cells causes lipid accumulation and oxidative stress, possibly mediated by p21, and it is a likely explanation for increased levels of p21 in NAFLD, reported previously. The gene discussed is CDKN1A; the disease is metabolic dysfunction-associated steatotic liver disease.